Immunotolerant properties of mesenchymal stem cells: Updated review

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Faiella, Whitney ^a   Atoui, Rony ^a  

^a Division of Plastic Surgery   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; PROSTAGLANDIN E2;

ANTERIOR MYOCARDIAL INFARCTION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL ACTIVATION; CELL DAMAGE; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; EXOSOME; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NATURAL KILLER CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; STROMA CELL; T LYMPHOCYTE; THERAPY EFFECT;

EID: 84956909705     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/1859567     Document Type: Review

References (74)

1. A. S. Go, D. Mozaffarian, V. L. Roger et al., "Heart disease and stroke statistics-2014 update: a report from the American Heart Association, " Circulation, vol. 129, no. 3, pp. e28-e292, 2014.
2. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Heart disease and stroke statistics-2015 update: a report from the American Heart Association, " Circulation, vol. 131, no. 4, pp. e29-e322, 2015.
3. J. Canty and G. Suzuki, "Myocardial perfusion and contraction in acute ischemia and chronic ischemic heart disease, " Journal ofMolecular and Cellular Cardiology, vol. 52, no. 4, pp. 822-831, 2012.
4. G. R. Heyndrickx, H. Baig, P. Nellens, I. Leusen, M. C. Fishbein, and S. F. Vatner, "Depression of regional blood flow and wall thickening after brief coronary occlusions, " The American Journal of Physiology, vol. 234, no. 6, pp. H653-H659, 1978.
5. A. Rony and R. C. J. Chiu, "Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns, " Stem Cells Translational Medicine, vol. 1, no. 3, pp. 200-205, 2012.
6. P. Lohan, C. M. Coleman, J. M. Murphy, M. D. Griffin, T. Ritter, and A. E. Ryan, "Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?" Stem Cell Research and Therapy, vol. 5, no. 4, pp. 99-109, 2014.
7. M. F. Pittenger and B. J. Martin, "Mesenchymal stem cells and their potential as cardiac therapeutics, " Circulation Research, vol. 95, no. 1, pp. 9-20, 2004.
8. A. Muraglia, R. Cancedda, and R. Quarto, "Clonal mesenchymal progenitors from human bonemarrow differentiate in vitro according to a hierarchical model, " Journal of Cell Science, vol. 113, no. 7, pp. 1161-1166, 2000.
9. A. Monsel, Y.-G. Zhu, S. Gennai, Q. Hao, J. Liu, and J. W. Lee, "Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells, " Anesthesiology, vol. 121, no. 5, pp. 1099-1121, 2014.
10. L. Biancone, S. Bruno, M. C. Deregibus, C. Tetta, and G. Camussi, "Therapeutic potential of mesenchymal stem cellderived microvesicles, " Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3037-3042, 2012.
11. J. Chen, C. Li, and L. Chen, "The role of microvesicles derived frommesenchymal stem cells in lung diseases, " BioMed Research International, vol. 2015, Article ID 985814, 6 pages, 2015.
12. D. Orlic, J. Kajstura, S. Chimenti et al., "Bone marrow cells regenerate infarcted myocardium, " Nature, vol. 410, no. 6829, pp. 701-705, 2001.
13. Y. Miyahara, N. Nagaya, M. Kataoka et al., "Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction, " Nature Medicine, vol. 12, no. 4, pp. 459-465, 2006.
14. J. A. Ankrum, J. F. Ong, and J. M. Karp, "Mesenchymal stem cells: immune evasive, not immune privileged, " Nature Biotechnology, vol. 32, no. 3, pp. 252-260, 2014.
15. R. J. Henning, "Stem cells in cardiac repair, " Future Cardiology, vol. 7, no. 1, pp. 99-117, 2011.
16. X.-P. Huang, Z. Sun, Y. Miyagi et al., "Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair, " Circulation, vol. 122, no. 23, pp. 2419-2429, 2010.
17. M. Nayan, A. Paul, G. Chen, R. C. Chiu, S. Prakash, and D. Shum-Tim, "Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction: in vitro and in vivo investigation, " Journal of Tissue Engineering, vol. 2, no. 1, Article ID 741213, 2011.
18. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringden, "HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells, " Experimental Hematology, vol. 31, no. 10, pp. 890-896, 2003.
19. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells, " Science, vol. 284, no. 5411, pp. 143-147, 1999.
20. M. M. Duffy, J. Pindjakova, S. A. Hanley et al., "Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor, " European Journal of Immunology, vol. 41, no. 10, pp. 2840-2851, 2011.
21. K. English, "Mechanisms of mesenchymal stromal cell immunomodulation, " Immunology and Cell Biology, vol. 91, no. 1, pp. 19-26, 2013.
22. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses, " Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
23. J. Maggini, G. Mirkin, I. Bognanni et al., "Mouse bone marrowderivedmesenchymal stromal cells turn activatedmacrophages into a regulatory-like profile, " PLoS ONE, vol. 5, no. 2, Article ID e9252, 2010.
24. S. P. Burr, F. Dazzi, and O. A. Garden, "Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance, " Immunology and Cell Biology, vol. 91, no. 1, pp. 12-18, 2013.
25. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, "Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2, " Blood, vol. 111, no. 3, pp. 1327-1333, 2008.
26. S. Dhingra, P. Li, X.-P. Huang et al., "Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stemcells and restores postinfarction ventricular function, " Circulation, vol. 128, no. 11, supplement 1, pp. S69-S78, 2013.
27. G. Ren, L. Zhang, X. Zhao et al., "Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide, " Cell Stem Cell, vol. 2, no. 2, pp. 141-150, 2008.
28. C. Xia and J. Cao, "Imaging the survival and utility of predifferentiated allogeneic MSC in ischemic heart, " Biochemical and Biophysical Research Communications, vol. 438, no. 2, pp. 382-387, 2013.
29. I. Bochev, G. Elmadjian, D. Kyurkchiev et al., "Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro, " Cell Biology International, vol. 32, no. 4, pp. 384-393, 2008.
30. A. Ribeiro, P. Laranjeira, S. Mendes et al., "Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrowexhibit different capability to suppress peripheral blood B, natural killer and T cells, " Stem Cell Research and Therapy, vol. 4, no. 5, article 125, 2013.
31. A. P. Beltrami, L. Barlucchi, D. Torella et al., "Adult cardiac stem cells are multipotent and support myocardial regeneration, " Cell, vol. 114, no. 6, pp. 763-776, 2003.
32. J. J. H. Chong, V. Chandrakanthan, M. Xaymardan et al., "Adult cardiac-residentMSC-like stemcellswith a proepicardial origin, " Cell Stem Cell, vol. 9, no. 6, pp. 527-540, 2011.
33. A. Rossini, C. Frati, C. Lagrasta et al., "Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin, " Cardiovascular Research, vol. 89, no. 3, pp. 650-660, 2011.
34. X. Z. Wang, H. Zhang, L. Nie, L. Xu, M. Chen, and Z. Ding, "Myogenic differentiation and reparative activity of stromal cells derived from pericardial adipose in comparison to subcutaneous origin, " Stem Cell Research and Therapy, vol. 5, no. 4, article 92, 2014.
35. I. Perea-Gil, M. Monguio-Tortajada, C. Galvez-Monton, A. Bayes-Genis, F. E. Borras, and S. Roura, "Preclinical evaluation of the immunomodulatory properties of cardiac adipose tissue progenitor cells using umbilical cord blood mesenchymal stem cells: a direct comparative study, " BioMed Research International, vol. 2015, Article ID 439808, 9 pages, 2015.
36. K. Le Blanc, I. Rasmusson, B. Sundberg et al., "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, " Lancet, vol. 363, no. 9419, pp. 1439-1441, 2004.
37. R. R. Makkar, M. J. Price, M. Lill et al., "Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model ofmyocardial infarction, " Journal of Cardiovascular Pharmacology andTherapeutics, vol. 10, no. 4, pp. 225-233, 2005.
38. L. C. Amado, A. P. Saliaris, K. H. Schuleri et al., "Cardiac repair with intramyocardial injection of allogeneicmesenchymal stem cells after myocardial infarction, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 32, pp. 11474-11479, 2005.
39. J. H. Houtgraaf, R. de Jong, K. Kazemi et al., "Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function, " Circulation Research, vol. 113, no. 2, pp. 153-166, 2013.
40. T. Saito, J.-Q. Kuang, B. Bittira, A. Al-Khaldi, and R. C.-J. Chiu, "Xenotransplant cardiac chimera: immune tolerance of adult stem cells, " The Annals of Thoracic Surgery, vol. 74, no. 1, pp. 19-24, 2002.
41. D. J. MacDonald, J. Luo, T. Saito et al., "Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model, " Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 4, pp. 1114-1121, 2005.
42. R. Atoui, J.-F. Asenjo, M. Duong, G. Chen, R. C.-J. Chiu, and D. Shum-Tim, "Marrow stromal cells as universal donor cells formyocardial regenerative therapy: their unique immune tolerance, "TheAnnals of Thoracic Surgery, vol. 85, no. 2, pp. 571-579, 2008.
43. W. Dai, S. L. Hale, B. J. Martin et al., "Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-termeffects, " Circulation, vol. 112, no. 2, pp. 214-223, 2005.
44. S. Dhingra, X.-P. Huang, and R.-K. Li, "Challenges in allogeneic mesenchymal stem cell-mediated cardiac repair, " Trends in Cardiovascular Medicine, vol. 20, no. 8, pp. 263-268, 2010.
45. M. Rigol, N. Solanes, S. Roura et al., "Allogeneic adipose stem cell therapy in acute myocardial infarction, " European Journal of Clinical Investigation, vol. 44, no. 1, pp. 83-92, 2014.
46. A. J. Poncelet, A.-L. Hiel, J. Vercruysse, D. Hermans, F. Zech, and P. Gianello, "Intracardiac allogeneicmesenchymal stem cell transplantation elicits neo-angiogenesis in a fully immunocompetent ischaemic swine model, " European Journal of Cardio- Thoracic Surgery, vol. 38, no. 6, pp. 781-787, 2010.
47. J. E. Cohen, B. P. Purcell, J. W. MacArthur Jr. et al., "A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in amurinemodel of ischemic cardiomyopathy, " Circulation. Heart failure, vol. 7, no. 4, pp. 619-626, 2014.
48. A. N. Patel, L. Geffner, R. F. Vina et al., "Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study, " Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 6, pp. 1631-1638, 2005.
49. C. J. Teng, J. Luo, R. C. J. Chiu, and D. Shum-Tim, "Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty, " Journal of Thoracic and Cardiovascular Surgery, vol. 132, no. 3, pp. 628-632, 2006.
50. Y. Yeghiazarians, Y. Zhang, M. Prasad et al., "Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy, " Molecular Therapy, vol. 17, no. 7, pp. 1250-1256, 2009.
51. J. H. Houtgraaf, W. K. den Dekker, B. M. van Dalen et al., "First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction, " Journal of the American College of Cardiology, vol. 59, no. 5, pp. 539-540, 2012.
52. A. H. Al Kindi, J. F. Asenjo, Y. Ge et al., "Microencapsulation to reduce mechanical loss of microspheres: implications in myocardial cell therapy, " European Journal of Cardiothoracic Surgery, vol. 39, no. 2, pp. 241-247, 2011.
53. G. Suzuki, B. R. Weil, M. M. Leiker et al., "Global intracoronary infusion of allogeneic cardiosphere-derived cells improves ventricular function and stimulates endogenous myocyte regeneration throughout the heart in swine with hibernating myocardium, " PLoS ONE, vol. 9, no. 11, Article ID e113009, 2014.
54. T. I. G. van der Spoel, K. R. Vrijsen, S. Koudstaal et al., "Transendocardial cell injection is not superior to intracoronary infusion in a porcinemodel of ischaemic cardiomyopathy: a study on delivery efficiency, " Journal of Cellular andMolecular Medicine, vol. 16, no. 11, pp. 2768-2776, 2012.
55. T. J. Kean, P. Lin, A. I. Caplan, and J. E. Dennis, "MSCs: delivery routes and engraftment, cell-targeting strategies, and immunemodulation, " Stem Cells International, vol. 2013, Article ID 732742, 13 pages, 2013.
56. P. Matzinger, "The danger model: a renewed sense of self, " Science, vol. 296, no. 5566, pp. 301-305, 2002.
57. R. C. J. Chiu, "Stealth immune tolerance in stemcell transplantation: potential for universal donors in myocardial regenerative therapy, "The Journal ofHeart and Lung Transplantation, vol. 24, no. 5, pp. 511-516, 2005.
58. S. Z. Bian, L. Zhang, L. Duan, X. Wang, Y. Min, and H. Yu, "Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model, " Journal of Molecular Medicine, vol. 92, no. 4, pp. 387-397, 2014.
59. C. F. Leite, T. R. Almeida, C. S. Lopes, and V. J. Dias da Silva, "Multipotent stem cells of the heart-do they have therapeutic promise?" Frontiers in Physiology, vol. 6, article 123, 2015.
60. M. J. Lovell and A. Mathur, "Republished review: cardiac stem cell therapy: progress from the bench to bedside, " Postgraduate Medical Journal, vol. 87, no. 1030, pp. 558-564, 2011.
61. E. Messina, L. de Angelis, G. Frati et al., "Isolation and expansion of adult cardiac stem cells from human and murine heart, " Circulation Research, vol. 95, no. 9, pp. 911-921, 2004.
62. K. Reddy, A. Khaliq, and R. J. Henning, "Recent advances in the diagnosis and treatment of acute myocardial infarction, " World Journal of Cardiology, vol. 7, no. 5, pp. 243-276, 2015.
63. A. A. Matar and J. J. H. Chong, "Stem cell therapy for cardiac dysfunction, " SpringerPlus, vol. 3, no. 1, pp. 440-453, 2014.
64. J. P. Zambrano, J. H. Traverse, T. D. Henry et al., "The impact of intravenous allogeneic human mesenchymal stem cells (provacel) on ejection fraction in patients withmyocardial infarction, " Circulation, vol. 116, no. 2, p. 202, 2007.
65. Mesoblast, Acute Graft Versus Host Disease 2015, Mesoblast, 2015, http://www.mesoblast.com/products/oncology/acute-graftversus- host-disease.
66. N. Kim and S. G. Cho, "New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation, " International Journal of Stem Cells, vol. 8, no. 1, pp. 54-68, 2015.
67. J. M. Hare, J. H. Traverse, T. D. Henry et al., "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction, " Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277-2286, 2009.
68. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., "Comparison of allogeneic vs autologous bonemarrow-derivedmesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial, "The Journal of theAmericanMedical Association, vol. 308, no. 22, pp. 2369-2379, 2012.
69. V. Y. Suncion, E. Ghersin, J. E. Fishman et al., "Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: an analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial, " Circulation Research, vol. 114, no. 8, pp. 1292-1301, 2014.
70. M. Mushtaq, D. L. DiFede, S. Golpanian et al., "Rationale and design of the percutaneous stemcell injection delivery effects on neomyogenesis in dilated cardiomyopathy (The POSEIDONDCM Study): aphase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologousmesenchymal stem cell vs. Allogeneicmesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy, " Journal of Cardiovascular Translational Research, vol. 7, no. 9, pp. 769-780, 2014.
71. D. D. Ascheim, A. C. Gelijns, D. Goldstein et al., "Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices, " Circulation, vol. 129, no. 22, pp. 2287-2296, 2014.
72. R. Makkar, R. Schatz, J. H. Traverse et al., "TCT-152 allogeneic heart stem cells to achieve myocardial regeneration (ALLSTAR): the six month phase I safety results, " Journal of the American College of Cardiology, vol. 64, no. 11, article B46, 2014.
73. Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction (AMICI), 2015, https://clinicaltrials.gov/ct2/show/NCT01781390.
74. Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects with Recent Acute Myocardial Infarction, 2015, https://clinicaltrials.gov/ct2/show/NCT00555828.